provided a novel gene signature including 7 PRGs (AIM2, PLCG1, ELANE, PJVK, CASP3, CASP6, and GSDMA) for predicting the prognosis of ovarian cancer (OC) patients and laid a foundation for further studies of the relationships between PRGs and immunity in OC (20). This evidence concerns the gene AIM2 and ovarian carcinoma.